Optical sensor of plasma constituents

• US 4,344,438 A
• Filed: 04/28/1980
• Issued: 08/17/1982
• Est. Priority Date: 08/02/1978
• Status: Expired due to Term

• Current Assignee: United States of America As Represented By The Secretary of The Department of Health Education and Welfare
• Original Assignee: United States of America As Represented By The Secretary of The Department of Health Education and Welfare
• Inventors: Schultz, Jerome S.
• Primary Examiner(s): Recla, Henry J.
• Assistant Examiner(s): Jaworski, Francis J.
• Application Number:
  US06/144,043
• Time in Patent Office: 841 Days
• Field of Search: 128/633, 128/634, 128/631, 356/39, 23/230 B, 23/901, 424/12, 250/364, 250/365
• US Class Current: 600/341
• CPC Class Codes: A61B 5/14528 invasively
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: G01N 2021/6484 Optical fibres
• CPC Class Codes: G01N 2021/7786 Fluorescence
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53

Abstract

A system for monitoring low molecular weight compounds in blood plasma in the body by optical means includes a chamber which can be inserted into the blood stream and which contains specific receptor sites for the plasma constituent to be analyzed. The chamber interior is isolated from the blood by a dialysis membrane which permits the plasma constituents to diffuse into the chamber. A competing ligand for the receptor sites is placed within the chamber, but due to its relatively large molecular size the competing ligand cannot escape through the dialysis membrane into the bloodstream. Light emitted or absorbed by the competing ligand gives a measure of the concentration of the selected low molecular weight compounds in the blood.

Claims

1. A device to optically measure the concentration of low molecular weight assay ligand, such as a plasma constituent, comprising:

a chamber insertable into a blood vessel including a selection means, in a wall of said chamber, for allowing at least one low molecular weight assay ligand to enter said chamber;

at least one competing ligand, inside said chamber, each said at least one competing ligand having a different identifiable optical property from the assay ligand to be measured, a quantitative measurement of said optical property being proportional to the concentration of said competing ligand, each said at least one competing ligand being a material which will not pass through said selection means;

at least one binding means having binding sites, confined inside said chamber in a selected region, for reversibly binding with the low molecular weight assay ligand to form a first complex of the binding means and assay ligand, and for reversibly binding with said competing ligand to form a second complex of the binding means and competing ligand, said competing ligand competing with the assay ligand for binding sites on said binding means;

a light source means in optical contact with the interior of said chamber for illuminating the unbound competing ligand and/or the second complex within said chamber; and

a detecting means in optical contact with said chamber for quantitatively measuring the indentifiable optical property of substantially only the unbound competing ligand or of substantially only the second complex.

2. A device according to claim 1, wherein said chamber is a part of a catheter.

3. A device according to claim 1, wherein said chamber is a part of a fiber optic catheter, said detecting means and said light source means being in said optical contact with said chamber through optic fibers.

4. A device according to claim 1, wherein said selection means is a dialysis membrane.

5. A device according to claim 4 wherein the identifiable optical property of each said at least one competing ligand is the absorption of light of particular wavelengths, and further including

a mirror, disposed inside said chamber so as to reflect the light passing through said unbound competing ligand or said second complex into said detecting means.

6. A device according to claim 1, wherein said competing ligand is chromophoric material.

7. A device according to claim 1, wherein said competing ligand is fluorecing labelled dextran, said binding means is concanavalin-A, and said assay ligand is glucose.

8. A device according to claim 1 or 7, wherein said light source is external to said chamber and communicates with said chamber by optic fibers.

9. A device according to claim 8, wherein said detecting means is external to said chamber and communicates with said chamber by optic fibers.

10. A device according to claim 1, wherein said light source is a light emitting diode in said chamber, and said detecting means includes a photocell in said chamber.

11. A device according to claim 10, further including recording means for recording the measurements made by said detecting means, and communication means for permitting communication between said recording means and said detecting means by radio waves.

12. A device according to claim 1 further including recording means for recording the measurements made by said detecting means.

13. A device according to claim 1, further including a plurality of binding means, inside said chamber, each binding means reversibly binding with a different assay ligand;

and

a plurality of competing ligands, inside said chamber, there being one competing ligand for each binding means to compete with the assay ligands for binding with said corresponding binding means.

14. A device according to claim 1, wherein the selected region for confining said binding means is located outside the light path.